BCAB (BioAtla) Inventory-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioAtla Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioAtla's Average Total Inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. BioAtla's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

BioAtla's Inventory-to-Revenue for the quarter that ended in Dec. 2024 stayed the same from Sep. 2024 (0.00) to Sep. 2024 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

BioAtla Inventory-to-Revenue Historical Data

The historical data trend for BioAtla's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla Inventory-to-Revenue Chart

BioAtla Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventory-to-Revenue

Get a 7-Day Free Trial

BioAtla Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioAtla's Inventory-to-Revenue

For the Biotechnology subindustry, BioAtla's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioAtla's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioAtla's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioAtla's Inventory-to-Revenue falls into.

Save Embed

;

Save Embed

;

BioAtla Inventory-to-Revenue Calculation

BioAtla's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

	Inventory-to-Revenue (A: Dec. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2023 )	+	Total Inventories (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )
=	( (0	+	0)	/	1 )	/	11
=	0					/	11
=	0.00

BioAtla's Inventory-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

	Inventory-to-Revenue (Q: Dec. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2024 )	+	Total Inventories (Q: Dec. 2024 ))	/	count )	/	Revenue (Q: Dec. 2024 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

BioAtla (NAS:BCAB) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioAtla's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioAtla's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	0	/	0
	=

BioAtla Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioAtla's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAtla Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

11085 Torreyana Road, San Diego, CA, USA, 92121

Website

https://www.bioatla.com

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Executives

Sylvia Mcbrinn	director
Short Jay M Phd	director, 10 percent owner, officer: Chief Executive Officer	C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez	officer: See Remarks	121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith	director, officer: President	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers	officer: Chief Medical Officer	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron	officer: Chief Financial Officer	901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy	director, 10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc	10 percent owner	104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc	10 percent owner	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran	director	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short	10 percent owner, officer: See Remarks	11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142